Wu X.-Y.,Guangxi Baise Peoples Hospital
Journal of Practical Oncology | Year: 2012
To evaluate the efficacy of neoadjuvant chemotherapy in patients with advanced ovarian cancer. One hundred and thirty patients with advanced ovarian cancer were randomly divided into neoadjuvant chemotherapy and postoperative chemotherapy groups with 65 cases in each group. The clinical data were compared between two groups. The operation time was (180 ± 15) min and (240 ± 25) min, and the blood loss was (380 ± 55) mL and (610 ± 80) mL in neoadjuvant chemotherapy group and postoperative chemotherapy group, respectively. Neoadjuvant chemotherapy group had 8 less cases with postoperative complications than postoperative chemotherapy group. The satisfaction rate and the 1y-, 3y-survival rates in neoadjuvant group were 29.2%, and 15.4%, 21.6% higher than those in postoperative group, respectively (all P < 0.05). Neoadjuvant chemotherapy has shorter operation time, less bleeding, less postoperative complications, and higher satisfaction and survival rate than postoperative chemotherapy for patients with advanced ovarian cancer.
Huang S.,Guangxi Baise Peoples Hospital |
Deng G.,Guangxi Baise Peoples Hospital |
Huang G.,Guangxi Baise Peoples Hospital |
Li Y.,Guangxi Baise Peoples Hospital |
And 2 more authors.
Chinese Journal of Clinical Oncology | Year: 2012
Objective: To compare the efficacy and adverse reactions of induction chemotherapy combined with concurrent chemoradiotherapy (IC/CCRT) with those of concurrent chemoradiotherapy (CCRT) alone for patients with advanced nasopharyngeal carcinoma (NPC). Methods: From September 2003 to May 2006, 200 patients with advanced NPC treated in the Guangxi Baise People's Hospital were enrolled in this study. The patients were randomly divided into two groups: the IC/CCRT group, and the CCRT group. Patients in the two groups received the same concurrent chemoradiotherapy regimen consisting of caboplatin (AUC = 6) at days 7, 28, and 49 of the radiotherapy. Patients in the IC/CCRT group received two cycles of induction thermotherapy consisting of 5-FU (750 mg/m 2) and caboplatin (AUC = 6) prior to the concurrent chemoradiotherapy. Results: The III and IV degree adverse reactions of the IC/CCRT and CCRT groups were 25.4% and 17.9%, respectively (P < 0.001). The 3-year overall survival rates of the IC/CCRT and CCRT groups were 83.5% and 79.4%, respectively (P = 0.3). No significant difference in the 3-year disease-free survival rate, as well as in the locoregional control rate and the distant control rate of advanced NPC patients was observed between the two groups. Conclusion: Compared with CCRT alone, IC/CCRT does not significantly improve the overall and disease-free survival rates of advanced NPC patients. In addition, the acute adverse reactions were more severe in the IC/CCRT group.